A minor subclone with additional CNAs was present in the primary TAM patient sample, whereas a new clone emerged in a 1° recipient. (A) Contig of del(16q22) breakpoint deduced by whole genome sequencing of the clone containing del(16q22) and del(16q24) in patient 1. Details are shown in supplemental Figure 6. (B) Breakpoint-specific PCR for the del(16q22) clone using genomic DNA from the original patient sample (1; PB in TAM phase), 1° to 8° xenografts (hCD45⁺ BM cells; Figure 3), and NC (negative control; PBMCs from a healthy adult). Cells from 1° to 8° recipients showed a bright band. The original patient sample showed a faint band, and direct sequencing revealed the presence of the deduced breakpoint for del(16q22). Human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) was used as an internal control. (C) Contig of del(3q24) breakpoint deduced by whole-genome sequencing. Details are shown in supplemental Figure 9. (D) Breakpoint-specific PCR for the del(3q24) clone using genomic DNA from the original patient sample (1; PB in TAM phase), 1° to 3° xenografts (hCD45⁺ BM cells, m2–5; Figure 4A), and NC. Cells from 2° and 3° recipients showed a bright band. No band was detected in the original patient sample, but a faint band was detected in the 1° recipient sample. hGAPDH was used as an internal control. Direct sequencing confirmed the presence of cells with the deduced breakpoint for del(3q24) in the 1° recipient.